Association between interleukin-10 promoter regions gene polymorphisms and susceptibility of ankylosing spondylitis

doi:10.3969/j.issn.2095-4344.2013.20.025

Abstract

Abstract:

BACKGROUND: Gene polymorphism in patients with ankylosing spondylitis, is likely to affect cytokine secretion pattern.
OBJECTIVE: To investigate the correlation between single nucleotide polymorphisms and haplotypes of interleukin-10 and the susceptibility of ankylosing spondylitis in Han population from Jiaodong Peninsula of China.
METHODS: The serum levels of interleukin-10 were measured with an enzyme-linked immunosorbent assay. The single nucleotide polymorphisms at positions -1082A/G, -819C/T and -592C/A in the interleukin gene promoter were analyzed using polymerase chain reaction and restriction fragment length polymorphism.
RESULTS AND CONCLUSION: 110 ankylosing spondylitis patients and 120 ethnic-matched healthy controls were included in this study. The serum levels of interleukin-10 in the ankylosing spondylitis group were significantly higher than that in the healthy control group (Z=-10.9, P < 0.001). Single nucleotide polymorphisms analysis showed there were no significant differences in the allelic and genotypic frequencies of -592A/C between the ankylosing spondylitis group and healthy control group. No -1082GG genotype was found in this study. The frequency of -1082G allele was increased in ankylosing spondylitis group when compared with that in the healthy control group (P=0.047). In a logistic regression analysis, the odds ratio of -1082AG genotype was 1.993 (95% confidence interval, 1.046-3.800, P=0.034) for ankylosing spondylitis. And the odds ratio of -819CC genotype was 3.125 (95% confidence interval, 1.246-7.836, P=0.015) for ankylosing spondylitis. Furthermore, haplotype analysis revealed that GCC haplotype could significantly increase the risk of ankylosing spondylitis when compared with the ATA haplotype (odd ratio=2.19; 95% confidence interval, 1.13-4.26; P=0.02). The results indicate that the gene haplotype of interleukin-10 has relationship with the susceptibility of ankylosing spondylitis in Han population from Jiaodong Peninsula of China.

Key words: tissue construction, tissue construction clinical practice, interleukin-10, gene polymorphism, ankylosing spondylitis, single nucleotide polymorphism, haplotype, cytokines, Han population, alleles, genotype, provincial grants-supported paper

CLC Number:

R318

Shen Cheng-kai, Lü Cheng-yu, Wang Ying-zhen, Zhang Hai-ning, Sui Ai-hua, Meng Fei . Association between interleukin-10 promoter regions gene polymorphisms and susceptibility of ankylosing spondylitis[J]. Chinese Journal of Tissue Engineering Research, 2013, 17(20): 3793-3800.

Figures/Tables 4

References

[1] Baraliakos X, Landewé R, Hermann KG,et al. Inflammation in ankylosing spondylitis: a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging.Ann Rheum Dis. 2005;64(5):730-734.

[2] Baraliakos X, Listing J, von der Recke A, et al. The natural course of radiographic progression in ankylosing spondylitis--evidence for major individual variations in a large proportion of patients.J Rheumatol. 2009;36(5):997-1002.

[3] van der Linden S, van der Heijde D. Ankylosing spondylitis. Clinical features. Rheum Dis Clin North Am. 1998;24(4): 663-676, vii.

[4] Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007; 369(9570):1379-1390.

[5] Sieper J, Rudwaleit M, Khan MA, et al. Concepts and epidemiology of spondyloarthritis.Best Pract Res Clin Rheumatol. 2006;20(3):401-417.

[6] Sieper J, Braun J, Rudwaleit M, et al. Ankylosing spondylitis: an overview.Ann Rheum Dis. 2002;61 Suppl 3:iii8-18.

[7] Kobelt G, Andlin-Sobocki P, Maksymowych WP. Costs and quality of life of patients with ankylosing spondylitis in Canada. J Rheumatol. 2006;33(2):289-295.

[8] Boonen A, van der Linden SM.The burden of ankylosing spondylitis. J Rheumatol Suppl. 2006;78:4-11.

[9] Reveille JD.The genetic basis of ankylosing spondylitis. Curr Opin Rheumatol. 2006;18(4):332-341.

[10] Brown MA, Kennedy LG, MacGregor AJ,et al. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthritis Rheum. 1997;40(10):1823-1828.

[11] Rahman P.Genetics of ankylosing spondylitis: an update.Curr Rheumatol Rep. 2007;9(5):383-389.

[12] Kim TH, Stone MA, Rahman P,et al. Interleukin 1 and nuclear factor-kappaB polymorphisms in ankylosing spondylitis in Canada and Korea.J Rheumatol. 2005;32(10):1907-1910.

[13] Baeten D, Van Damme N, Van den Bosch F, et al. Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalpha. Ann Rheum Dis. 2001;60(8):750-755.

[14] Rudwaleit M, Siegert S, Yin Z,et al. Low T cell production of TNFalpha and IFNgamma in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. Ann Rheum Dis. 2001;60(1):36-42.

[15] Turner DM, Williams DM, Sankaran D, et al. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet. 1997;24(1):1-8.

[16] Wilson AG, Symons JA, McDowell TL, et al. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A. 1997;94(7):3195-3199.

[17] Kingo K, Rätsep R, Kõks S, et al. Influence of genetic polymorphisms on interleukin-10 mRNA expression and psoriasis susceptibility. J Dermatol Sci. 2005;37(2):111-113.

[18] Kaluza W, Leirisalo-Repo M, Märker-Hermann E,et al. IL10.G microsatellites mark promoter haplotypes associated with protection against the development of reactive arthritis in Finnish patients. Arthritis Rheum. 2001;44(5):1209-1214.

[19] Lee WY, Chang YH, Lo MK, et al. Polymorphisms of cytotoxic T lymphocyte-associated antigen-4 and cytokine genes in Taiwanese patients with ankylosing spondylitis. Tissue Antigens. 2010;75(2):119-126.

[20] van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361-368.

[21] Kozaci LD, Sari I, Alacacioglu A, et al. Evaluation of inflammation and oxidative stress in ankylosing spondylitis: a role for macrophage migration inhibitory factor. Mod Rheumatol. 2010;20(1):34-39.

[22] Costa GC, da Costa Rocha MO, Moreira PR,et al. Functional IL-10 gene polymorphism is associated with Chagas disease cardiomyopathy. J Infect Dis. 2009;199(3):451-454.

[23] Edwards-Smith CJ, Jonsson JR, Purdie DM, et al. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology. 1999;30(2):526-530.

[24] Smith JA, Märker-Hermann E, Colbert RA. Pathogenesis of ankylosing spondylitis: current concepts. Best Pract Res Clin Rheumatol. 2006;20(3):571-591.

[25] Khan MA, Ball EJ. Genetic aspects of ankylosing spondylitis. Best Pract Res Clin Rheumatol. 2002;16(4):675-690.

[26] Vazquez-Del Mercado M, Garcia-Gonzalez A, Muñoz-Valle JF, et al. Interleukin 1beta (IL-1beta), IL-10, tumor necrosis factor-alpha, and cellular proliferation index in peripheral blood mononuclear cells in patients with ankylosing spondylitis.J Rheumatol. 2002;29(3):522-526.

[27] Goedecke V, Crane AM, Jaakkola E,et al. Interleukin 10 polymorphisms in ankylosing spondylitis. Genes Immun. 2003; 4(1):74-76.

[28] Poli F, Nocco A, Berra S,et al. Allele frequencies of polymorphisms of TNFA, IL-6, IL-10 and IFNG in an Italian Caucasian population. Eur J Immunogenet. 2002;29(3): 237-240.

[29] Du R,Pan SY,Lu BX. Jiepouxue Zazhi. 2006;29(6):686-689.杜冉,潘速跃,陆兵勋.中国汉族人群白细胞介素10启动子区基因多态性的等位基因频率[J].解剖学杂志,2006,29(6):686-689.

[30] Sun F, Sun Y, Zhang D,et al. Association of interleukin-10 gene polymorphism with cachexia in Chinese patients with gastric cancer. Ann Clin Lab Sci. 2010;40(2):149-155.

[31] Moraes MO, Santos AR, Schonkeren JJ, et al. Interleukin-10 promoter haplotypes are differently distributed in the Brazilian versus the Dutch population. Immunogenetics. 2003;54(12): 896-899.

[32] Wu MS, Wu CY, Chen CJ,et al. Interleukin-10 genotypes associate with the risk of gastric carcinoma in Taiwanese Chinese. Int J Cancer. 2003;104(5):617-623.